Receptor tyrosine kinases(RTKs),a category of transmembrane receptors,have gained significant clinical attention in oncology due to their central role in cancer pathogenesis.Genetic alterations,including mutations,amp...Receptor tyrosine kinases(RTKs),a category of transmembrane receptors,have gained significant clinical attention in oncology due to their central role in cancer pathogenesis.Genetic alterations,including mutations,amplifications,and overexpression of certain RTKs,are critical in creating environments conducive to tumor development.Following their discovery,extensive research has revealed how RTK dysregulation contributes to oncogenesis,with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation,survival and progression.These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer.As a result,RTKs have emerged as primary targets in anticancer therapeutic development.Over the past two decades,this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors(TKIs),now effectively utilized in treating various cancer types.In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer.We explored the various alterations and overexpression of specific receptors across different malignancies,with special attention dedicated to the examination of current RTK inhibitors,highlighting their role as potential targeted therapies.By integrating the latest research findings and clinical evidence,we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.展开更多
基金funded by a grant of the Romanian Government(bursa Henri Coandă)funded by a grant from the Romanian Academy of Scientists 2023-2024+3 种基金funded by an international grant of the European Hematology Association(EHA-SWG Immunotherapy Project 2024–CAR NK cells for tumor associated macrophage immunomodulation—a new era of immunotherapy)by a bilateral collaboration grant between Romania and Moldova(PN-IVP8-8.3-ROMD-2023-0036)funded by a national grant of the Romanian Research Ministry–PNRR 2024-2026(PNRR/2022/C9/MCID/18,Contract No.760278/26.03.2024)supported in part by the R35 CA 197706 grant from the National Cancer Institute.
文摘Receptor tyrosine kinases(RTKs),a category of transmembrane receptors,have gained significant clinical attention in oncology due to their central role in cancer pathogenesis.Genetic alterations,including mutations,amplifications,and overexpression of certain RTKs,are critical in creating environments conducive to tumor development.Following their discovery,extensive research has revealed how RTK dysregulation contributes to oncogenesis,with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation,survival and progression.These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer.As a result,RTKs have emerged as primary targets in anticancer therapeutic development.Over the past two decades,this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors(TKIs),now effectively utilized in treating various cancer types.In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer.We explored the various alterations and overexpression of specific receptors across different malignancies,with special attention dedicated to the examination of current RTK inhibitors,highlighting their role as potential targeted therapies.By integrating the latest research findings and clinical evidence,we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.
